You are here: Industry Insights > Market News > Pharma firm to pay $1.3B fine for vaccine scandal

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Pharma firm to pay $1.3B fine for vaccine scandal

biospectrumasiaOctober 19, 2018

Tag: Vaccine , scandal

Favorites

Changchun Changsheng Life Sciences Ltd has been charged with a huge fine of $1.3 billion for falsifying production records in a scandal that prompted a nationwide crackdown on the vaccine industry.

Although no injuries were reported from use of Changsheng Life Science's rabies vaccines, authorities ordered a recall of its products from Chinese and foreign markets.

The pharma firm had used expired materials, mixed different batches of products and failed to test them properly. It was revealed that the company destroyed records to conceal its misconduct. 14 of its executives as well as its chairwoman were arrested while dozens were banned working in the drugs sector.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:PureTech affiliate Karuna advances schizophrenia candidate

Next:Robot addresses British MPs over future of AI

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Pharma firm to pay $1.3B fine for vaccine scandal | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1

B11 100ml amber plastic vaccine bottle

Influenza Vaccine(Split Virion),Inactivated with good efficacy

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect by hualan biological

WHO-PQ Influenza Vaccine

OPV(Poliomyelitis(Live)Vaccine(Monkey Kidney Cell).Oral

High-standard and high quality Influenza Vaccine (Split virion), inactivated

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral

Pharma firm to pay $1.3B fine for vaccine scandal

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>